Melan-A/MART-1 Mouse anti-Human, Mouse, Rat, Alexa Fluor 750, Clone: M2-7C10, Novus Biologicals
Mouse Monoclonal Antibody
Manufacturer: Novus Biologicals NBP233148AF750
DescriptionMelan-A/MART-1 Monoclonal antibody specifically detects Melan-A/MART-1 in Human,Mouse,Rat samples. It is validated for Western Blot,ELISA,Immunohistochemistry,Immunocytochemistry,Immunofluorescence,Immunohistochemistry (Paraffin),Immunohistochemistry (Frozen).
|Western Blot, ELISA, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen|
|Antigen LB39-AA, Antigen SK29-AA, Mart 1 Melan A, MART1MART-1, melan-A, melanoma antigen recognized by T-cells 1, Protein Melan-A|
|Store at 4°C in the dark.|
|This antibody recognizes a protein doublet of 20-22kDa, identified as MART-1 (Melanoma Antigen Recognized by T cells 1) or Melan-A. MART-1 is a newly identified melanocyte differentiation antigen recognized by autologous cytotoxic T lymphocytes. Seven other melanoma associated antigens recognized by autologous cytotoxic T cells include MAGE-1, MAGE-3, tyrosinase, gp100, gp75, BAGE-1, and GAGE-1. Subcellular fractionation shows that MART-1 is present in melanosomes and endoplasmic reticulum. This MAb labels melanomas and other tumors showing melanocytic differentiation. It is also a useful positive-marker for angiomyolipomas. It does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin.|
|ELISA, Immunocytochemistry, Immunofluorescence, Immunohistochemistry, Immunohistochemistry (Paraffin), Western Blot|
|Alexa Fluor™ 750|
|50 mM sodium borate with 0.05% sodium azide|
|Recombinant human Melan-A protein was used as immunogen to generate the Melan-A antibody.|
|Human, Mouse, Rat|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok